tetano
Editor, Senior Moderator
Br J Haematol
. 2021 Jan 22.
doi: 10.1111/bjh.17272. Online ahead of print.
Early mortality benefit with COVID-19 convalescent plasma: a matched control study
Aarthi G Shenoy[SUP] 1 [/SUP], Aaron Z Hettinger[SUP] 2 3 [/SUP], Stephen J Fernandez[SUP] 3 [/SUP], Joseph Blumenthal[SUP] 3 [/SUP], Valentina Baez[SUP] 1 [/SUP]
Affiliations
Abstract
Convalescent plasma can provide passive immunity during viral outbreaks, but the benefit is uncertain for the treatment of novel coronavirus disease 2019 (COVID-19). Our goal is to assess the efficacy of COVID-19 convalescent plasma (CCP). In all, 526 hospitalized patients with laboratory-confirmed SARS-CoV-2 at an academic health system were analyzed. Among them, 263 patients received CCP and were compared to 263 matched controls with standard treatment. The primary outcome was 28-day mortality with a subanalysis at 7 and 14 days. No statistical difference in 28-day mortality was seen in CCP cases (25?5%) compared to controls (27%, P = 0?06). Seven-day mortality was statistically better for CCP cases (9?1%) than controls (19?8%, P < 0?001) and continued at 14 days (14?8% vs. 23?6%, P = 0?01). After 72 h, CCP transfusion resulted in transitioning from nasal cannula to room air (median 4 days vs. 1 day, P = 0?02). The length of stay was longer in CCP cases than controls (14?3 days vs. 11?4 days, P < 0?001). Patients with COVID-19 who received CCP had a decreased risk of death at 7 and 14 days, but not 28 days after transfusion. To date, this is the largest study demonstrating a mortality benefit for the use of CCP in patients with COVID-19 compared to matched controls.
Keywords: COVID-19; convalescent plasma; mortality; oxygenation; transfusion.
. 2021 Jan 22.
doi: 10.1111/bjh.17272. Online ahead of print.
Early mortality benefit with COVID-19 convalescent plasma: a matched control study
Aarthi G Shenoy[SUP] 1 [/SUP], Aaron Z Hettinger[SUP] 2 3 [/SUP], Stephen J Fernandez[SUP] 3 [/SUP], Joseph Blumenthal[SUP] 3 [/SUP], Valentina Baez[SUP] 1 [/SUP]
Affiliations
- PMID: 33482025
- DOI: 10.1111/bjh.17272
Abstract
Convalescent plasma can provide passive immunity during viral outbreaks, but the benefit is uncertain for the treatment of novel coronavirus disease 2019 (COVID-19). Our goal is to assess the efficacy of COVID-19 convalescent plasma (CCP). In all, 526 hospitalized patients with laboratory-confirmed SARS-CoV-2 at an academic health system were analyzed. Among them, 263 patients received CCP and were compared to 263 matched controls with standard treatment. The primary outcome was 28-day mortality with a subanalysis at 7 and 14 days. No statistical difference in 28-day mortality was seen in CCP cases (25?5%) compared to controls (27%, P = 0?06). Seven-day mortality was statistically better for CCP cases (9?1%) than controls (19?8%, P < 0?001) and continued at 14 days (14?8% vs. 23?6%, P = 0?01). After 72 h, CCP transfusion resulted in transitioning from nasal cannula to room air (median 4 days vs. 1 day, P = 0?02). The length of stay was longer in CCP cases than controls (14?3 days vs. 11?4 days, P < 0?001). Patients with COVID-19 who received CCP had a decreased risk of death at 7 and 14 days, but not 28 days after transfusion. To date, this is the largest study demonstrating a mortality benefit for the use of CCP in patients with COVID-19 compared to matched controls.
Keywords: COVID-19; convalescent plasma; mortality; oxygenation; transfusion.